CDC Recommendations

CDC* Recommendations2

CDC guidelines support MenB vaccination for 16 year olds

ACIP‡ recommends that a MenB vaccine series may be administered to healthy adolescents and young adults aged 16 through 23 years to provide short-term protection against most strains of MenB. The preferred age for MenB vaccination is 16 through 18 years. The decision to vaccinate should be made based on shared clinical decision-making.2

The Affordable Care Act mandates insurance coverage for all vaccinations administered in accordance with ACIP recommendations. Health care providers should contact their individual plan to determine specific coverage and reimbursement requirements and adoption timeframes.4 MenB vaccines are available through the Vaccines for Children program.3

Click here for more information from ACIP.
Click here for more information from the CDC* or
Download the CDC's Vaccine Information Statement on MenB.
 

Individuals at increased risk for MenB should be vaccinated, according to ACIP5

ACIP recommends certain persons aged ≥10 years who are at increased risk for meningococcal disease should receive MenB vaccine. These persons include:

  • Persons who are in a MenB outbreak situation or at increased risk for meningococcal disease
  • Persons with persistent complement component deficiencies§
  • Persons with anatomic or functional asplenia, including sickle cell disease
  • Microbiologists routinely exposed to isolates of Neisseria meningitidis
Learn about MenB

*CDC=Centers for Disease Control and Prevention.

†If at increased risk of disease or based on discussion with patient's family.

‡ACIP=Advisory Committee on Immunization Practices.

§Including inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or who are taking eculizumab (Soliris®,  Alexion Pharmaceuticals, Inc).

Contact your Pfizer Sales Representative or call a Vaccine Specialist at
1-844-439-2571.
Pfizer Home

Clinical Information

Find out about TruSupport
TRUMENBA clinical studies

TRUMENBA is the only MenB vaccine that demonstrated cross-coverage of diverse MenB strains.1

TRUMENBA is the only MenB vaccine that demonstrated cross-coverage of diverse MenB strains by targeting both subfamilies, A and B, of fHBP.1

See the data
The science behind TRUMENBA

Only TRUMENBA targets both subfamilies, A and B, of fHBP.1

See the science